Palatin Technologies Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ___________ to __________ Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) (609) 495-2200(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Name of Each Exchangeon Which RegisteredNYSE American Common Stock, par value $0.01 per share Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934, as amended during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act: Large accelerated filer Non-accelerated filer Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date (May 12,2026): 1,779,275 PALATIN TECHNOLOGIES, INC.Table of Contents PageSpecial Note Regarding Forward-Looking StatementsiiPART I – FINANCIAL INFORMATIONItem 1. Financial Statements (Unaudited)Consolidated Balance Sheets as of March 31, 2026 and June 30, 20251Consolidated Statements of Operations for the Three and Nine months ended March 31, 2026 and 20252Consolidated Statements of Changes in Stockholders’ Equity (Deficiency) for the Three and Nine months ended March 31,20263Consolidated Statements of Changes in Stockholders’ Deficiency for the Three and Nine months ended March 31, 20254Consolidated Statements of Cash Flows for the Nine months ended March 31, 2026 and 20255Notes to Consolidated Financial Statements6Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations19Item 3. Quantitative and Qualitative Disclosures About Market Risk23Item 4. Controls and Procedures23PART II – OTHER INFORMATION24Item 1. Legal Proceedings24Item 1A. Risk Factors24Item 2. Unregistered Sales of Equity Securities and Use of Proceeds24Item 3. Defaults Upon Senior Securities24Item 4. Mine Safety Disclosures24Item 5. Other Information24Item 6. Exhibits25Signatures26i Special Note Regarding Forward-Looking Statements In this Quarterly Report on Form 10-Q (this “Quarterly Report”) references to “we,” “our,” “us,” the “Company” or “Palatin” meanPalatin Technologies, Inc. and its subsidiary. Statements in this Quarterly Report, as well as oral statements that may be made by us or by our officers, directors, or employeesacting on our behalf, that are not historical facts constitute “forward-looking statements,” which are made pursuant to the safe harborprovisions of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statementsin this Quarterly Report do not constitute guarantees of future performance. Investors are cautioned that statements that are not strictlyhistorical facts contained in this Quarterly Report, including, without limitation, the following are forward-looking statements: ●our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays inreceiving funds as a result of economic disruptions;●our expectation that we will incur losses for the foreseeable future and may never achieve or maintain profitability;●our business, financial condition, and results of operations may be adversely affected by increases in costs of and delays inconducting human clinical trials and the performance of our contractors and suppliers, reduction in our productivity or theproductivity of our contractors and suppliers, supply chain constraints, and labor shortages;●whether Boehring